AG真人官方

Myomo, Inc. (MYO) reported strong top-line growth for the period ended June 30, 2025 with revenue of $9.65 million in the quarter, up 28% year-over-year, and $19.48 million for the six months, up 73% versus prior year. Higher sales were driven by more units and higher average selling prices following CMS reimbursement updates. Gross profit rose in absolute terms but gross margin narrowed to 62.7% in Q2 from 70.8% a year ago due to higher material and manufacturing overhead costs tied to a new headquarters and facility.

The company reported a quarterly net loss of $4.63 million (loss per share $0.11) and a six-month net loss of $8.10 million as operating expenses increased substantially: R&D +99% and selling, clinical & marketing +88% for the quarter. Cash, cash equivalents and short-term investments totaled about $15.48 million at June 30, 2025, and management states this funding is expected to cover operations for at least 12 months. The company drew $2.5 million on its revolving line and $1.5 million on its term loan during the quarter and disclosed a material weakness in IT general controls that is being remediated.

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gil Aharon report shared beneficial ownership of 7,359,046 securities of Myomo, Inc., representing approximately 9.9% of the company鈥檚 outstanding common stock based on 37,801,070 shares reported by the issuer. The reported total comprises 3,595,788 shares of common stock and 3,763,258 shares issuable upon exercise of pre-funded warrants.

The filing states the pre-funded warrants include a blocker provision that prevents exercise to the extent it would push beneficial ownership above 9.99%, so the actual number of shares beneficially owned after giving effect to blockers is lower. Each reporting person discloses no sole voting or dispositive power and shared voting and dispositive power over the 3,595,788 common shares. The reporting persons certify the securities were acquired in the ordinary course and not to influence control of the issuer.

Myomo, Inc. (MYO) 鈥� Form 4 insider transaction

Chief Medical Officer Harry Kovelman reported the automatic sale of 13,054 common shares on 30 June 2025 at $2.19 per share. The transaction is coded 鈥淔,鈥� indicating the shares were withheld solely to cover income taxes arising from the vesting of restricted stock units on 28 June 2025. After the sale, Kovelman still beneficially owns 140,618 shares, held directly. No derivative securities were acquired or disposed of, and no additional transactions are disclosed.

The filing appears to be a routine tax-related share withholding rather than a discretionary market sale and does not materially change insider ownership levels.

Myomo, Inc. (MYO) 鈥� Form 4 filing: Chief Financial Officer David A. Henry reported a Code 鈥淔鈥� transaction on 30 June 2025, in which 23,587 shares of common stock were withheld and sold at $2.19 per share solely to satisfy income-tax obligations arising from the vesting of restricted stock units (RSUs) on 28 June 2025. After the automatic sale, the executive continues to hold 427,900 shares in direct ownership. No derivative security activity was reported, and the filing discloses no additional purchases or open-market sales. Such tax-withholding dispositions are routine and generally neutral with respect to the executive鈥檚 long-term ownership position and the company鈥檚 fundamentals.

Myomo, Inc. (MYO) 鈥� Form 144 filing: The notice discloses a proposed sale of 23,587 common shares by David Henry through Morgan Stanley, targeted for 30 June 2025 on the NYSE American. The shares have an aggregate market value of $51,655.53, equating to roughly 0.07 % of the company鈥檚 35,978,922 shares outstanding, indicating an immaterial proportion of total equity.

The securities derive from the vesting of restricted stock units (RSUs) on 28 June 2025, when 65,000 shares were acquired from Myomo. In addition, the filer sold 8,373 shares on 06 June 2025 for gross proceeds of $24,867.81. No other financial data or operational commentary is provided in the filing.

Because the planned sale represents a very small percentage of outstanding shares and does not involve new share issuance, dilution is not a concern. Nonetheless, investors often monitor insider transactions for sentiment signals; repeated insider selling can be interpreted cautiously, even when associated with equity compensation events such as RSU vesting.